Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves: A Prospective, Randomized, Controlled Non-Inferiority Trial

NCT06476301 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT06476301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06476301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves: A Prospective, Randomized, Controlled Non-Inferiority Trial
Lead sponsor
RenJi Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
August 1, 2024
Completion date
December 31, 2026
Enrollment
250 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anticoagulation